by Nick Veringmeier | Feb 25, 2026 | Business Development, Life Sciences Marketing
How do you run customer interviews that prevent expensive mistakes? In life sciences, it is surprisingly easy to build the wrong product. Not because the science is weak, but because many startups develop in isolation. They assume the market will automatically value...
by Nick Veringmeier | Feb 24, 2026 | Business Development, Life Sciences Marketing
The Netherlands’ new coalition agreement, presented as a blueprint for the country through 2030, contains a subtle but significant shift in how the government views biotechnology. Life sciences and biotechnology are explicitly identified as strategic economic domains,...
by Nick Veringmeier | Dec 30, 2025 | Business Development, Life Sciences Marketing
In 2025, the Dutch life sciences sector showed where it is willing to commit, not just what it wants to become. This recap looks at the Netherlands as it operates in practice. Regions with clear roles. Campuses built for execution. Companies moving from early promise...
by Nick Veringmeier | Nov 3, 2025 | Business Development
In the race to bring new therapies to market, few forces shape a biotech company’s future as much as its partnerships. The right alliance can cut years off development. The wrong one can set you back just as far. Across the life sciences, partnerships and strategic...
by Nick Veringmeier | Aug 27, 2025 | Business Development
Biotech lives and dies on funding. No matter how strong the science, companies without capital stall. Lab work stops, milestones slip, and competitors pull ahead. In a sector where a single clinical trial can cost tens of millions, investor outreach is not optional....
by Nick Veringmeier | May 6, 2025 | Business Development
The Line in the Sand While the U.S. is tying science to politics, the EU just made a move biotech can’t ignore. At La Sorbonne, Ursula von der Leyen launched “Choose Europe”: a €500 million initiative to pull top researchers, fund long-term science, simplify...
